GlobeNewswire: NICOX Contains the last 10 of 1128 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T20:06:36ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/22/2850746/0/en/Nicox-s-Shareholder-Letter.html?f=22&fvtc=4&fvtv=30137Nicox's Shareholder Letter2024-03-22T06:30:00Z<![CDATA[Dear Shareholder,]]>https://www.globenewswire.com/news-release/2024/03/22/2850746/0/fr/Nicox-Lettre-aux-Actionnaires.html?f=22&fvtc=4&fvtv=30137Nicox - Lettre aux Actionnaires2024-03-22T06:30:00Z<![CDATA[Madame, Monsieur, Cher Actionnaire,]]>https://www.globenewswire.com/news-release/2024/03/20/2849092/0/en/Results-from-Mont-Blanc-Phase-3-Trial-of-Nicox-s-NCX-470-in-Glaucoma-Published-in-the-American-Journal-of-Ophthalmology.html?f=22&fvtc=4&fvtv=30137Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology2024-03-20T06:30:00Z<![CDATA[Press Release]]>https://www.globenewswire.com/news-release/2024/03/20/2849092/0/fr/Nicox-Publication-de-r%C3%A9sultats-de-l-%C3%A9tude-de-phase-3-Mont-Blanc-sur-le-NCX-470-dans-le-glaucome-dans-la-revue-American-Journal-of-Ophthalmology.html?f=22&fvtc=4&fvtv=30137Nicox : Publication de résultats de l’étude de phase 3 Mont Blanc sur le NCX 470 dans le glaucome dans la revue American Journal of Ophthalmology2024-03-20T06:30:00Z<![CDATA[Communiqué de presse]]>https://www.globenewswire.com/news-release/2024/03/13/2845155/0/en/Nicox-Updates-on-Corporate-Pipeline-and-Financing-Perspectives-and-Will-Hold-a-Webcast-on-March-18-2024.html?f=22&fvtc=4&fvtv=30137Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 20242024-03-13T06:30:00Z<![CDATA[Press Release]]>https://www.globenewswire.com/news-release/2024/03/13/2845155/0/fr/Nicox-fait-le-point-sur-les-perspectives-de-son-d%C3%A9veloppement-de-son-portefeuille-de-produits-et-de-son-financement-et-tiendra-une-r%C3%A9union-par-webcast-le-18-mars-2024.html?f=22&fvtc=4&fvtv=30137Nicox fait le point sur les perspectives de son développement, de son portefeuille de produits et de son financement et tiendra une réunion par webcast le 18 mars 20242024-03-13T06:30:00Z<![CDATA[Communiqué de presse]]>https://www.globenewswire.com/news-release/2024/03/05/2840087/0/en/Nicox-Announces-Presentation-of-Data-on-NCX-470-at-the-2024-American-Glaucoma-Society-Annual-Meeting.html?f=22&fvtc=4&fvtv=30137Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting2024-03-05T06:30:00Z<![CDATA[Press Release]]>https://www.globenewswire.com/news-release/2024/03/05/2840087/0/fr/Nicox-Pr%C3%A9sentation-de-donn%C3%A9es-sur-le-NCX-470-au-Congr%C3%A8s-Annuel-2024-de-l-American-Glaucoma-Society.html?f=22&fvtc=4&fvtv=30137Nicox : Présentation de données sur le NCX 470 au Congrès Annuel 2024 de l’American Glaucoma Society2024-03-05T06:30:00Z<![CDATA[Communiqué de presse]]>https://www.globenewswire.com/news-release/2024/03/01/2838991/0/en/Number-of-voting-rights-as-of-February-29-2024.html?f=22&fvtc=4&fvtv=30137Number of voting rights as of February 29, 20242024-03-01T16:45:00Z<![CDATA[Nicox SA Société anonyme with a registered capital of € 50,299,694]]>https://www.globenewswire.com/news-release/2024/03/01/2838991/0/fr/Nombre-de-droits-de-vote-au-29-f%C3%A9vrier-2024.html?f=22&fvtc=4&fvtv=30137Nombre de droits de vote au 29 février 2024 2024-03-01T16:45:00Z<![CDATA[Nicox SA Société anonyme au capital de 50 299 694 euros]]>